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Prognostically controlled comparison of dialysis and renal transplan-
tation. Because the comparison of survival in patients with renal fail-
ure treated by dialysis and transplantation may be biased by pretreat-
ment prognostic differences in the patients who receive these two
therapies, we quantified the pretreatment prognosis of all 430 dialysis
and transplant patients who began therapy for end-stage renal disease
at two hospitals from 1970 to 1980. Five pretreatment factors had a sta-
tistically significant adverse effect on survival: age, duration of diabe-
tes, left ventricular failure, myocardial infarction, and other serious
comorbid illness. Dialysis patients had a worse pretreatment prognosis
than transplant patients did. When we controlled for these pretreat-
ment differences, the actuarial 5-year patient survivals were 80% for
dialysis (D), 79% for cadaver transplantation (CT), and 91% for living
donor transplantation (LDT), (P = 0.9 for CT vs. D, and P = 0.05 for
LDT vs. D). This similarity in survival with dialysis and cadaver trans-
plantation was quite different from the results obtained when pretreat-
ment prognosis was not controlled; the uncontrolled 5-year patient sur-
vivals were 43% for D, 77% for CT, and 89% for LDT (P < 0.001 for
CT vs. D, and P < 0.001 for LDT vs. D). Our data suggest that the
major factor determining differences in survival with dialysis and renal
transplantation is not the relative efficacy of the two treatments but the
pretreatment prognostic status of the patients chosen to receive them.
Une comparaison contrôlée de facon pronostique entre Ia dialyse et Ia
transplantation rénale. Puisque la comparaison de Ia survie des malades
en insuffisance rénale traitCs par dialyse ou par transplantation peut
être biaisée par des differences pronostiques pré-thérapeutiques entre
les malades qui recoivent ces deux traitements, nous avons quantiflé
le pronostic pré-therapeutique de l'ensemble des 430 malades dialyses
et transplantés qui ont commence le traitement de leur insuffisance
rénale dans deux hôpitaux de 1970 a 1980. Cinq facteurs pré-
therapeutiques possédaient un effet adverse statistiquement significatif
sur Ia survie: l'age, Ia durée du diabète, une insuffisance ventriculaire
gauche, un infarctus du myocarde, et une autre maladie sérieuse
associée. Les dialyses avaient un pronostic pré-thérapeutique plus
mauvais que les transplantés. Lorsque nous avons contrôlé ces
differences pre-therapeutiques, Ia survie actuarielle a 5 ans des malades
était de 80% pour la dialyse (D), 79% pour la transplantation
cadaverique (CT), et 91% pour Ia transplantation avec donneur vivant
(LDT) (P = 0,9 pour CT contre D, et P = 0,05 pour LDT contre D).
Cette similitude de survie en dialyse ou aprés transplantation
cadaverique était très différente des résultats obtenus lorsque le
pronostic pré-thérapeutique n'était pas contrôlé; les survies non
contrôlées a 5 ans des malades étaient de 43% pour D, 77% pour CT,
et 89% pour LDT (P < 0,001 pour CT contre D, et P < 0,001 pour LDT
contre D). Nos données suggèrent que le facteur principal determinant
les differences de survie en dialyse ou aprés transplantation rénale
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n'est pas l'efficacité relative des deux traitements, mais l'état pronos-
tique pré-therapeutique des malades choisis pour les recevoir.
Although there is a large number of studies [1—11] compar-
ing survival with dialysis and renal transplantation in the treat-
ment of end-stage renal disease, the published results have a
potential scientific flaw—the patients chosen for transplanta-
tion may be prognostically different from patients continued on
dialysis therapy [12—16]. Therefore, apparent beneficial or det-
rimental effects of transplantation may be related to the better
or worse prognosis of the patients who receive a transplant
rather than to the efficacy of transplantation itself. To provide
a more scientifically valid comparison of these two major thera-
pies for endstage renal disease, we have quantified the pretreat-
ment prognosis and corrected for the prognostic disparities in
patients treated by dialysis and transplantation.
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Methods
Patients. We studied all patients (N = 430) who received
their first definitive treatment (dialysis or kidney transplanta-
tion) for chronic renal failure at the Royal Victoria Hospital or
the Montreal General Hospital from 1 January 1970 to 31 De-
cember 1980. They were identified from the lists of patients
who had received dialysis or kidney transplantation at either
hospital and from the medical records of all patients with dis-
charge diagnoses of chronic renal failure or uremia.
Data collection. We separated the information used to pre-
dict prognosis from that related to the effects of replacement
therapy by using only pretreatment information to character-
ize patients' clinical state. For this purpose, replacement
therapy was judged to have begun with the start of regular dial-
ysis therapy or with a first kidney transplant, whichever came
first. In the initial data collection, which involved patients
started on treatment from 1970 to 1975, we examined the pa-
tients' medical records for 85 variables in the following catego-
ries: demography; primary renal diagnosis; duration, severity
and complications of uremia; presence and severity of comor-
bid illnesses; and the level of general physical, social, and
psychological functioning. The results of this study led to the
development of an age-equivalence index for predicting sur-
vival in renal failure, which has been published [16]. For pa-
tients who started treatment from 1976 to 1980, we collected
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information on a limited number of factors that were shown to
have statistically significant effects on survival in the patients
treated during the earlier period.
We used the information collected after the start of replace-
ment therapy to identify major changes in therapy and to as-
certain survival. We obtained complete follow-up information
on 413 patients (96%). The main reason for loss to follow-up
was that patients had moved out of the geographical area. Dur-
ing the study period, 188 patients (45%) died.
We collected the data from medical records using a two-
stage procedure that has been described previously [161. To
avoid the bias that might occur if alterations were made in the
way that information was collected in patients with different
outcomes, we did not tell the person collecting the information
the precise purpose of the study, and we usually collected the
prognostic information before collecting information on the
outcome. Since the person who collected the patient data in the
initial study could not be kept blind to the results of that study,
we used another person, who was unaware of the first set of
results, to collect the data on patients treated from 1976 to
1980.
Statistics. We assessed the effect of various factors on sur-
vival, determined by life table analysis, by using the regres-
sion approach devised by Cox [171. The basic assumption of
this method is that a worse prognostic status, which can result
from a patient having more of one characteristic or an addi-
tional different characteristic, multiplies the risk of dying by a
factor that remains constant over the period of follow-up. We
tested these assumptions on patients treated in the initial pe-
riod and found that they fitted the data very well [161.
With this approach, we first examined the effect of the treat-
ing hospital on survival. Because the survival rates in the two
hospitals were similar, we pooled the data in subsequent analy-
sis. Next, as previously reported [161, we examined each of the
potential prognostic variables for an effect on survival in the
first study period (1970 to 1975). Since this represented an hy-
pothesis-generating study that might produce some statisti-
cally significant effects by chance alone, we tested variables
that appeared significant in the first data set for an effect in the
patients treated later on (1976 to 1980). To obtain the major
prognostic characteristics, we then did a stepwise procedure
using only variables that had produced statistically significant
effects in both data sets. We used the whole data set (1970 to
1980) for this analysis to maximize our power to identify prog-
nostically important variables.
To remove any confounding by the effects of transplanta-
tion, we reevaluated prognosis using cadaver and living donor
transplantation as time-dependent covariates. The two kinds of
transplant were included in the analysis and were treated on an
equal basis with the prognostic variables. The analysis esti-
mated the risk or benefit associated with each variable to maxi-
mize the accuracy of predicting survival for all the members of
the population. Thus, when there was an overlap or potential
confounding between the effects of treatment and a prognostic
variable, the analysis distributed the overlapping effect be-
tween the two in a way that best explained the survival data.
By using transplant as a time-dependent covariate, we allowed
for the waiting period between starting ESRD treatment and
getting a kidney transplant. With this approach dialysis was
given credit for keeping patients alive until they received a
Table 1. Characteristics of study population
1970—75 1976—80 Total
Age (mean SD) 45.4 17.4 51.9 17.3 48.6 17.6
Sex
Male 134 (61%) 118 (56%) 252 (59%)
Female 86 (39%) 92 (44%) 178 (41%)
Renal disease
Glomerulonephritis 57 (26%) 35 (17%) 92 (21%)
Chronic pyelonephritis 39 (18%) 18 (9%) 57 (13%)
Polycystic kidneys 16 (7%) 17 (8%) 33 (8%)
Diabetic nephropathy 16 (7%) 15 (7%) 31 (7%)
Hypertensive disease 5 (2%) 5 (2%) 10 (2%)
Miscellaneous other
disease 18 (8%) 8 (4%) 26 (6%)
Uncertain cause 69(31%) 112 (53%) 181 (42%)
Treatment
Cadaver transplant 87 (40%) 44 (2 1%) 131 (30%)
Living donor transplant 30 (14%) 8 (4%) 38 (9%)
Dialysis alone 103 (47%) 158 (75%) 261 (61%)
Hospital
Hospital 1 132 (60%) 116 (55%) 248 (58%)
Hospital 2 88 (40%) 94 (45%) 182 (42%)
transplant. At transplantation, patients were changed to the
equivalent point on the transplant curve and were compared
with dialysis patients who had been on ESRD treatment for the
same length of time as the transplanted patient. This method
of analysis is essential to avoid the bias that is otherwise cre-
ated by the waiting period for transplantation [18]. After prog-
nosis had been assessed, we then calculated survival with dial-
ysis and transplantation after adjustment for the prognostic
characteristics identified.
To assess the impact of transplantation on actual lives saved
or lost, we also did pairwise comparisons of mortality after
transplantation with that expected if dialysis and the relevant
kind of transplant were equivalent treatments. We assumed no
difference between dialysis and transplantation (null hypoth-
esis) and calculated the expected mortality by applying the
overall mortality rate to the period of follow-up experienced by
the transplant patients. The effect of the kind of transplanta-
tion that was not being evaluated was removed by including it
as a time-dependent covariate in the analysis, and we used the
effects of the prognostic variables to adjust the expected mor-
tality for the clinical status of the patients chosen for transplan-
tation. A chi-square test was used to compare observed and ex-
pected deaths after transplantation.
Results
Study population. The patients studied are described in Ta-
ble 1. Because some of the subsequent analyses give separate
results for the two study periods (1970 to 1975; 1976 to 1980),
we have given the characteristics of patients in each period as
well as those for the population as a whole. We cannot de-
scribe the exact racial mixture of patients in this study, be-
cause race was not routinely recorded in the medical record;
however, the majority of patients at both hospitals were white.
Hemodialysis was the predominant mode of dialysis; 72% of
the patients either started on hemodialysis or switched later to
this form of therapy. There is a difference between the pa-
tients in the two periods in age, distribution of renal diag-
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noses, and the proportion of patients receiving renal trans-
plants. These differences, however, did not affect survival: in
the 1970—1975 study period, the 1-year and 5-year survivals
were 77% and 54%; in the 1976 to 1980 period, they were 76%
and 56%.
Prognostic assessment. Table 2 shows the pretreatment
characteristics that had a statistically significant effect in the
1970 to 1975 period and also gives the P value for their effect
in 1976 to 1980. In addition to the variables originally found to
be statistically significant [161, three other variables that were
not coded for in the original analysis were found to have a sta-
tistically significant effect on survival: ischemia showing on
electrocardiogram; other severe comorbid illness; and the abil-
ity of patients to care for themselves. The determination of "is-
chemia on electrocardiogram" was based on probable or defi-
nite ischemia diagnosed by the cardiologist making out the of-
ficial EKG report. Other comorbid illnesses included a variety
of illnesses judged to be likely to have a markedly adverse ef-
fect on survival by a nephrologist who was blind to the out-
come of the patients. There were 5 patients with cancer, 6 with
a myeloproliferative disorder, 2 with severe collagen vascular
disease, and 6 with miscellaneous other life-threatening ill-
nesses. "Ability to care for self" reflected patients' ability to
carry out activities of daily living after they had developed se-
vere renal failure (serum creatinine, greater than 5 mg/dl) but
before they started on therapy for end-stage renal disease.
Of the characteristics shown in Table 2, 16 had statistically
significant (P < 0.05) effects on survival for the 1976 to 1980
period. The prognostic features that had statistically signifi-
cant effects on survival in both study periods were age and var-
iables relating to the following comorbid illnesses: diabetes,
congestive heart failure, atherosclerosis, and miscellaneous
other illnesses. To reduce redundant information caused by the
high correlation of individual variables with each other, we did
a stepwise analysis on the whole data set (1970 to 1980) using
these 16 characteristics. With this approach, we identified 5
characteristics that made an independent contribution to sur-
vival: age, duration of diabetes, left-sided heart failure as evi-
denced by pulmonary edema, a history of myocardial
infarction, and other severe comorbid illness. The prognostic
characteristics identified included 3 variables (age, duration of
diabetes, and left-sided heart failure) that we had previously
used to construct a prognostic index based on patients treated
from 1970 to 1975 [161. Of the remaining 2 variables, "other se-
vere comorbid illness" was not coded in previous analyses.
The addition of myocardial infarction reflects an increased
power of the analysis owing to the larger number of patients in
the current study (430 vs. 220).
The relative risk associated with the 5 prognostic variables
is shown in column one of Table 3. These estimates of prog-
nostic risk might be biased if a prognostic characteristic were
associated with an increased likelihood of getting a transplant
and if transplantation were to have a significant effect on mor-
tality. To avoid this potential for confounding by the effects of
transplantation, we did a second analysis in which the first
transplantation (cadaver donor and living related donor trans-
plants were treated separately) was treated as a time depen-
dent covariate: Patients were included in the group receiving
dialysis until they had a kidney transplant and after that point
were included in one of the two transplant categories. The re-
Table 2. Pretreatment characteristics that had a statistically significant
(P < 0.05) effect on survival in the 1970 to 1975 period tested in the
1976 to 1980 period
P value for prognostic
Characteristic
effects
1970 to 1975 1976 to 1980
Age <0.001 <0.001
Renal diagnosis
Glomerulonephritis 0.02 0.13
Pyonephrosis 0.001 0.14
Uremia
Number of physical signs of uremia 0.002
Motor neuropathy 0.003 0.68
Pericarditis 0.01 0.12
Comorbid illness
Diabetes
Diabetes mellitus 0.004 <0.001
Duration of diabetes 0.001 <0.001
Oral hypoglycemic agents for
diabetes 0.001 <0.001
Adult-onset diabetes <0.001 0.001
Congestive heart failure
Cardiomegaly <0.001 <0.001
Pulmonary edema <0.001 <0.001
Jugular venous distension <0.001 <0.001
Paroxysmal nocturnal dyspnea 0.001 0.003
Atherosclerosis
Myocardial infarction 0.03 <0.001
Angina pectoris 0.006 <0.001
Intermittent claudication <0.001 <0.001
Absent pedal pulses 0.01 0.01
Carotid bruits or absent pulsation 0.009 0.08
Ischemia on electrocardiogram 0.002 0.02
Miscellaneous
Duration of untreated hypertension 0.001 0.8
Hypertensive retinal complications 0.04 0.2
History of more than one episode
of pneumonia 0.005 0.75
Severe depression diagnosed by a
psychiatrist 0.008 0.6
Other serious comorbid illness 0.03 <0.001
Ability to care for self 0.004 <0.001
a Not tested because data were not collected for the 1976 to 1980
period.
sults of this analysis, which are shown in the second column
of Table 3, do not suggest that there was confounding by the
effects of transplantation. We did a further check by limiting
the analysis to the patients treated by dialysis alone. The re-
sults were similar.
Comparison of dialysis and transplantation (without prog-
nostic adjustment). The survival for patients treated by dial-
ysis and cadaver and living related donor transplantation are
shown in Fig. 1. The survival of patients in the dialysis curve
is dated from the point of starting dialysis. Patients who were
initially dialyzed and later transplanted contributed to dialysis
survival up to the point of receiving a transplant and then be-
gan to contribute to survival at the start of the relevant trans-
plant curve. A newer method of analysis [18] that allows for the
variable "waiting period for transplantation" led to similar
conclusions: Survival with both cadaver and living related
donor transplantation was significantly better than survival
with dialysis therapy. The relative risk of death compared with
dialysis therapy was 0.38 (95% confidence interval: 0.25 to
0.58; P < 0.001) for cadaver transplantation and 0.13 (95%
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Table 3. Relative risk of deatha associated with the prognostic
characteristics
Unadjusted Adjusted for
for effects of effects of
Prognostic transplan- transplan-
characteristic tation P tationb J'
Age (10 years) 1.8 <0.001 1.8 <0.001
Duration of diabetes
(10 years) 1.8 <0.001 1.8 <0.001
Left-sided heart
failure 1.9 <0.001 1.9 <0.001
Myocardial infarction 1.4 <0.05 1.4 0.10
Other severe comor-
bid illness 4.2 <0.001 4.3 <0.001
a The relative risk of death is the risk of death in patients with a
prognostic characteristic divided by the risk of death in those without it.
Thus, a relative risk of 1.9 associated with left-sided heart failure means
that patients with heart failure had approximately twice the risk of dying
as patients without heart failure had.
b To remove effects that were due to transplantation rather than to
the prognostic characteristics themselves, we included transplantation
as an independent variable in this analysis.
Living
Prognostic
characteristic
Dialysis
alone
(N = 261)
Cadaver
transplant(N = 131)
donor
transplant(N = 38)
Total
population(N = 430)
Age
(mean SD) 57.1 15.4 36.5 11.3 31.8 12.5 48.6 17.6
Diabetes melli-
tusk' 38 (15%) 13 (10%) 1 (3%) 52 (12%)
Left ventricular
failure 166 (64%) 40 (31%) 16 (42%) 222 (52%)
Myocardial in-
farction 57 (22%) 3 (2%) 0 (0%) 60 (14%)
Other comor-
bid illness 17 (7%) 0 (0%) 1 (3%) 18 (4%)
a The percentages shown in parentheses reflect the proportion of
patients on the relevant treatment who had this abnormality. For
example, of patients treated by dialysis alone, 38 out of 261 (15%) had
diabetes mellitus.
I I b The duration of diabetes was similar in the diabetic patients treated
4 by dialysis alone (mean = 12.9 yrs.), cadaver transplant (mean = 14.42 yrs.) and living donor transplant (mean 14.0 yrs.).
Years of follow-up
Fig. 2. Survival with dialysis and transplantation with con! rol for pre-
treatment prognostic d(fferences. Survivals are calculated for the av-
erage pretreatment status of cadaver transplant patients, which corre-
sponds to an age of 41.6 without adverse prognostic factors.
confidence interval: 0.05 to 0.34; P < 0.001) for living donor
transplantation.
Pretreatment prognosis of dialysis and transplant patients.
When we compared the distribution of prognostic factors in
dialysis and transplant patients (Table 4), we found that dial-
ysis patients were older and sicker than patients chosen for
transplantation. For instance, the average age of patients
treated by dialysis alone was 57.1 years as compared with 36,5
years in cadaver transplant patients and 31.8 in living donor
transplant patients. The frequencies of diabetes, left ventric-
ular failure, myocardial infarction, and other severe comorbid
illness were also higher in dialysis than in transplant patients.
Comparison of dialysis and transplantation (with prognostic
adjustment). To correct for this prognostic bias, we calculated
survival curves after adjusting for the pretreatment differences
in the patients chosen for dialysis and transplantation. The
curves shown in Fig. 2 are calculated for the average prognos-
tic risk of cadaver transplant patients. This corresponds to an
age of 41.6 years without comorbid illness. When pretreatment
prognostic differences are removed, the curves for cadaver
transplantation and dialysis overlap. The estimated relative
risk of death for cadaver transplantation compared with dial-
ysis was 1.03 (95% confidence interval: 0.64 to 1.66; P = 0.9)
showing no difference in the risk of death with these two thera
pies. The survival curve for living donor transplantation ap-
100
LMngdonortransplant
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Years of follow-up
Fig. 1. Survival with dialysis and transplantation without control for
pretreatment prognostic dj'ferences.
Table 4. Distribution of prognostic factors in dialysis and transplant
patientsa
a)
>
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0
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peared better than for dialysis. The estimated relative risk of
death for living donor transplantation compared with dialysis
was 0.42(95% confidence interval: 0.15 to 1.19; P = 0.05), sug-
gesting but not proving a beneficial effect. These results con-
trast with the unadjusted results (Fig. 1), which suggested that
both kinds of transplantation had a statistically significant ben-
eficial effect on survival.
To determine whether the results obtained with prognostic
adjustment might be affected by an over-conservative method
of choosing prognostic variables we tried a less conservative
approach: We adjusted for all the 25 variables listed in Table
2, The relative risks for transplantation versus dialysis were
unchanged (1.0 for cadaver transplantation and 0.44 for living
donor transplantation). We were also concerned that the re-
sults might be affected by a change in the risk associated with
the prognostic variables over time. For instance, the risk as-
sociated with left ventricular failure drops from 4.2 in the first
6 months after starting treatment to 1.05 after 3 years. Be-
cause the average risk of 1.9 is applied in our analyses, a pa-
tient who was transplanted at 3 years might have been at less
risk of dying from left ventricular failure than we allowed for
in the prognostic adjustment. When, however, we allowed for
these changes in prognostic effects over time, the results were
unchanged. The relative risk of death was 0.96 for cadaver
transplantation and 0.44 for living donor transplantation.
A further concern relates to the marked difference in age
between dialysis and transplant patients, which means that
some age groups are not represented in the transplant group—
there was only one transplant patient aged 60 or over, whereas
126 of the dialysis patients were in this age group. It might
therefore be argued that the effect of age in our analyses is
heavily weighted by the poor results of old dialysis patients and
that the application of this overall age effect to transplant pa-
tients is an extrapolation that may distort the results. To meet
this criticism, we excluded patients 60 years of age or older
from the analysis and recalculated the effect of age and of
transplantation on survival. The results were similar to our pre-
vious analyses. The relative risk was 1.7 for each 10 years of
age, and the relative risk of death compared with dialysis treat-
ment was 1.17 for cadaver transplantation and 0.39 for living
donor transplantation.
A final concern relates to the assumption that the effect of
age and other prognostic variables were the same in dialysis
and transplant treatment groups. This assumption was testable
for three variables (age, duration of diabetes, and left ventric-
ular failure) that had sufficient numbers in the dialysis and
transplant groups. For age, the relative risk associated with
each 10 years was 1.7 for dialysis and 1.6 for transplantation
(P value for the difference, >0.1). For duration of diabetes, the
risk associated with each 10 years was 1.7 for dialysis and 1.9
for transplantation (P value for the difference, >0.1). For left
ventricular failure, the relative risk was 2.5 for dialysis and 0.8
for transplantation (P value for the difference, <0.05). This dis-
crepancy appeared to be explained by the marked decrease in
the effect of left ventricular failure over time—patients were
usually transplanted after the major prognostic effect of left ven-
tricular failure had disappeared. This interpretation is sup-
ported by the finding that, when the time dependency of the
prognostic effect of heart failure was accounted for, transplan-
tation did not significantly modify the effect of the left ventric-
Type of Observed Expected
transplant deaths deathsa
Cadaver 32 31.5 0.9(N = 131)
Living Donor 4 9.1 0.05(N = 38)
The expected deaths were calculated from the overall mortality rate
(dialysis and transplant patients) and the pretreatment prognostic risk of
the patients who received a transplant.
b The P value is based on a x2 test comparing observed and expected
deaths.
Table 6. Comparison of observed and expected deaths for functioning
and failed transplants
Function of Observed Expected
graft deaths deathsa
16 20.5 0.2
16 10.9 0.09
1 8.3 <0.01
3 0.7 <0.01
a The expected deaths were calculated from the overall mortality rate
(dialysis and transplant patients) and the pretreatment prognostic risk of
patients with a failed or functioning transplant.
b The P value is based on a x2 testcomparing observed and expected
deaths.
ular failure (P > 0.1). The assumption of similar prognostic ef-
fects on dialysis and transplantation cannot be tested for the re-
maining two prognostic variables, which are history of myo-
cardial infarction and other comorbid illness. However, these
variables did not appear to have a major effect on the compari-
son of dialysis and transplantation; when we omitted these two
variables from the analysis; the results for comparison with
dialysis were a relative risk of 0.95 for cadaver transplantation
and 0.41 for living donor transplantation.
Impact of transplantation on lives savedor lost. To express
the above results in the more tangible form of numbers of lives
saved or lost owing to transplantation, we compared observed
and expected mortality for the transplant patients. The ex-
pected mortality was calculated from the overall mortality rate
of the population and the pretreatment prognostic risk of the
patients who received a transplant. A similarity of observed
and expected deaths would fit with the null hypothesis of no
difference in treatment efficacy between dialysis and transplan-
tation. The results are shown in Table 5. Column one shows
the observed mortality, and column two gives the expected
mortality. The mortality with cadaver transplantation was simi-
lar to that expected from pretreatment prognosis: The ob-
served deaths were 32, versus the expected 31.5. For living do-
nor transplantation, observed deaths were 4, and the number
expected was 9.1.
Functioning and failed transplants. The above analyses as-
sess the effect of the clinical decision to give a dialysis patient
a renal transplant. They do not, however, distinguish between
the biological effects of a functioning graft and a failed one, and
they do not show which phase of transplant therapy accounted
for the mortality observed. Therefore, we did a further analy-
sis to distinguish between the mortality with a functioning
Table 5. Deaths after transplantation compared with deaths expected
if dialysis and transplantation were equivalent treatments
Type of
transplant
Cadaver
Cadaver
Living donor
Living donor
Functioning
Failed
Functioning
Failed
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versus a failed transplant. The results are shown in Table 6. A
functioning transplant appeared to have a beneficial effect on
survival, whereas a failed transplant appeared to have a det-
rimental effect. For cadaver transplantation, neither result
was statistically significant. For living donor transplantation,
the beneficial effect while the transplant was functioning and
the detrimental effect after it failed were both statistically
significant.
Discussion
Our study is not the first to compare the survival of patients
treated by dialysis and transplantation. The majority of pub-
lished studies Fl—5, 7—9], however, fail to allow for the dif-
ferent pretreatment prognoses of patients treated by dialysis
and transplantation. Of the studies that do attempt to equalize
prognosis [6, 10, 11], only one study [101 corrects for factors
others than age. After excluding patients with diabetes and
those with hypertension, the authors [10] compared survival
with dialysis and transplantation after adjustment for age, re-
nal diagnosis, and number of associated diseases. The relative
risk of death on transplantation compared with dialysis was
1.26 (P = 0.7) for cadaver transplants and 0.51 (P < 0.01) for
living donor transplants. Confidence in these results is limited,
however, because the authors did not make a thorough search
for all of the factors other than treatment that might have af-
fected the survival of their patients. Also, no direct compari-
son was made of the pretreatment prognosis of the dialysis and
transplant patients in their study.
In our study, we did an extensive search involving a large
number of potential prognostic factors. We also demonstrated
a potent bias in favor of transplantation. When we adjusted for
this prognostic bias, cadaver transplantation had no effect on
the survival expected with dialysis therapy. Living donor trans-
plantation had a beneficial effect that did not quite reach sta-
tistical significance. The lack of overall effect of transplanta-
tion was explained by a favorable effect while the transplant
was functioning and a detrimental effect after it had failed. Our
data suggest that the main explanation for differences in sur-
vival with dialysis and transplantation is not the relative ef-
ficacy of the two treatments. The major determining factor in
our study was the pretreatment prognostic status of the pa-
tients chosen for transplantation.
The main potential limitations of this research relate to the
number of patients studied, the choice of the prognostic var-
iables and estimate of risk associated with them, and the effect
of graft survival on patient survival. Although the number of
patients studied was not small (N = 430), it did allow for a
sizeable type II error (the chance of concluding that no differ-
ence exists between treatments that are really different). The
confidence intervals for relative risk obtained in our study do
not exclude a beneficial or detrimental effect on survival for ei-
ther cadaver or living related transplants. Further studies with
very much larger numbers of patients are needed to exclude the
possibility that we missed real differences in our study.
Although we cannot exclude the possibility that we over-
looked prognostically important variables, we did an extensive
search that included 85 variables in five categories—demo-
graphic, renal diagnosis, uremic severity and complications,
comorbid illness, social and psychologic functioning. The final
variables used in prognostic adjustment represented a con-
servative approach to avoid overcorrecting for variables whose
effect might be due to chance alone. When we used a less con-
servative approach, however, and adjusted for 25 variables that
had statistically significant effects in the first data set, we got
similar results.
The estimate of risk that we used to adjust for prognostic
characteristics in our study do not appear to be biased by con-
founding with the effects of transplantation or by a change in
the effect of the prognostic variables over time. The risk es-
timates that we used were adjusted for the effects of transplan-
tation. Furthermore, when we used the risk estimates obtained
in patients treated by dialysis alone, the results were similar.
The effects of the prognostic characteristics do tend to change
over time; however, when we did an analysis allowing for this
change, the results for the comparison of dialysis and trans-
plantation were unchanged. A further issue related to our es-
timates of prognostic risk is whether the effects of the prognos-
tic variables were similar in dialyzed and transplanted pa-
tients. For the three variables for which such a test could he
made (age, duration of diabetes, and left ventricular failure),
the results supported a similar effect in different treatment
groups. The other two characteristics (history of myocardial in-
farction and other comorbid illness) were too infrequent in
transplanted patients to allow the similarity of their effect to be
tested. These two variables, however, did not appear to have
a major effect on the results of treatment comparison. Omis-
sion of a history of myocardial infarction and other comorbid
illness from the analysis did not change the results for compari-
son of dialysis and transplantation.
With the functioning transplants appearing to be more ben-
eficial than failed transplants (Table 6), it is possible that the
rate of graft failure affected our results. The one-year graft sur-
vival was 76% for cadaver transplants and 87% for living do-
nor transplants. Because these graft survivals are better than
many in the published literature [19—21], it seems unlikely that
poor graft survival has biased our results. Nevertheless, higher
graft survival rates may be achievable with newer therapies
such as cyclosporin A [22, 23]. To the extent that these im-
proved graft survivals are achievable without having long-term
adverse effects on the patient [24], the effects of cadaver trans-
plantation may be more favorable in the future than our study
suggests. Conversely, transplantation would be a less attrac-
tive therapy in centers with substantially lower graft survivals
than the levels reported in our study.
It may be that transplantation has beneficial effects on the
quality of life that are not revealed in our study, which focuses
solely on duration of survival. A recent study of quality of life
in cadaver transplant patients [251 showed, however, a similar
pattern of results. The quality of life in patients with function-
ing transplants was slightly better than it was in patients Ofl
dialysis who had not been transplanted. This slight superiority
of transplantation was offset, however, by a poorer quality of
life after the transplant had failed. Taken together with our data
showing an increased risk of death in patients with failed trans-
plants, these findings suggest that perhaps cadaver transplan-
tation should be limited to patients who have a high probabil-
ity of prolonged graft survival. Further work is needed to de-
termine the break-even point—the duration of graft survival
necessary to confer an overall beneficial effect on the duration
and quality of life of transplanted patients.
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Although our study focuses on the comparison between dial-
ysis and transplantation, other comparisons of treatment for
end-stage renal disease may also be biased by differences in the
patients chosen to receive them. For instance, differences in
survival on home versus hospital dialysis [26] may be ex-
plained by the better pretreatment prognosis of patients who
are well enough to carry out their own dialysis at home [14].
The conventional method for removing such biases is to ran-
domize allocation of therapy. However, surveys such as ours
have some attractive features as another method for dealing
with the same questions. First, they are more feasible, cost
less, and avoid some of the ethical dilemmas [271 posed by
clinical trials. Second, they yield results that are more easily
extrapolated to patient care for several reasons: (a) The pa-
tients studied are not preselected by their willingness to give
informed consent or by their absence of comorbid illnesses,
which often lead to exclusion from a trial. (b) The treatment
evaluated is the one actually administered to patients in rou-
tine care and is not altered by the structure of a trial, an altera-
tion that may lead to more rigid adherence to protocol, more
use of ancillary investigations and treatments, and potential
placebo effects in patients who receive both the experimental
and comparison treatments. (c) The rapidity with which re-
sults can be obtained decreases the likelihood that the technol-
ogy being evaluated will be superseded by newer methods by
the time the study has been completed.
These advantages of sophisticated survey methods do not
mean that they can replace experimental clinical trials as the
gold standard for determining therapeutic efficacy. All such
studies, including ours, involve major assumptions that are not
completely provable. The main assumptions of the method that
we used are (a) that individual prognostic factors and treat-
ments multiply the risk of dying by a factor that remains con-
stant over the period of follow-up, (b) that the effect of two or
more prognostic factors is the multiplication of their individual
risks, (c) that we have not missed major prognostic variables,
and (d) that pretreatment status is a good indicator of prognos-
tic risk throughout the period of follow-up. We have dealt with
assumptions a, b, and c in this and previous publications [16].
The issue raised in d is the subject of ongoing research. How-
ever, regardless of the thoroughness of our testing, some el-
ement of doubt will remain. It is the reduction or elimination
of such doubt that is the main advantage of well-conducted ex-
perimental studies. We would suggest that the two methodolo-
gies (surveys and experiments) should be seen as complement-
ing each other. A rational approach would be to begin with a
survey that can identify prognostic factors and estimate treat-
ment effects using the most sophisticated methodology avail-
able. The data from such studies can then provide estimates on
which clinicians can base decision until trials are performed,
can suggest hypotheses to be tested in clinical trials, and can
provide information that will be useful in the planning and
analysis of those trials that are performed. We believe that this
combined approach can increase the efficiency and scientific
validity of therapeutic evaluation, both in nephrology and in
other areas of clinical medicine.
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